Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial
Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with oral sorafenib shows manageable safety profile but modest antitumor activity in patients with BCLC stage C advanced HCC.
Authors
- Chunyong Wen (ORCID: https://orcid.org/0000-0003-0640-7293)
- Lujun Shen (ORCID: https://orcid.org/0000-0002-7936-0206)
- Letao Lin (ORCID: https://orcid.org/0000-0002-6750-8883)
- Shuanggang Chen
- Weijun Fan (ORCID: https://orcid.org/0000-0002-8757-647X)
- Hongliang Zou (ORCID: https://orcid.org/0000-0003-3911-7532)
- Gulijiayina Nuerhashi
- Ying Liu (ORCID: https://orcid.org/0000-0001-5718-7804)
- Fei Cao (ORCID: https://orcid.org/0000-0003-0083-1528)
- Yujia Wang (ORCID: https://orcid.org/0000-0001-9716-1115)
- Lin Xie (ORCID: https://orcid.org/0000-0001-5385-7380)
- Hendrick Tan
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Sun Yat-sen University (CN)
- Guangzhou University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- BMC Medicine
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1186/s12916-025-04110-1
- Citations
- 7
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 9.25